
CAI (CAI) Stock Forecast & Price Target
CAI (CAI) Analyst Ratings
Bulls say
Caris Life Sciences is thriving as a precision medicine company due to their strong management team, successful cancer screening test results, and multiple partnerships with biopharma companies. They have seen a decline in shares, but are expected to continue growing through new tests and technology, despite facing competition and potential risks.
Bears say
Caris Life Sciences is a patient-centric, next-generation AI TechBio company that develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. While the company's data from its ACHIEVE 1 study is impressive, we believe it is challenging to compare its data set of ~3k samples to larger data sets of ~20-40k+ samples in the space. Additionally, we have concerns about the company's financial fitness and its ability to comply with legal requirements and receive adequate coverage and reimbursement from third-party payers.
This aggregate rating is based on analysts' research of CAI and is not a guaranteed prediction by Public.com or investment advice.
CAI (CAI) Analyst Forecast & Price Prediction
Start investing in CAI (CAI)
Order type
Buy in
Order amount
Est. shares
0 shares